Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

OBJECTIVE: To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). METHODS: In this double-blind, phase II trial, 203 patients with PsA were randomised 1:1:1 to placebo, deucravacitinib 6 mg once...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, Deodhar, Atul A, van der Heijde, Désirée, Behrens, Frank, Kivitz, Alan J, Neal, Jeffrey, Kim, Jonghyeon, Singhal, Shalabh, Nowak, Miroslawa, Banerjee, Subhashis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120409/
https://www.ncbi.nlm.nih.gov/pubmed/35241426
http://dx.doi.org/10.1136/annrheumdis-2021-221664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120409/
https://www.ncbi.nlm.nih.gov/pubmed/35241426
http://dx.doi.org/10.1136/annrheumdis-2021-221664

Ejemplares similares